Company intelligence / Profile preview
Terns Pharmaceuticals
Foster City, California, United Statesternspharma.com ↗
- Ownership
- Public · TERN
- Employees
- ~66
- Development stage
- Phase 2
01
Overview
Positive Phase 1 trial results for TERN-601 (oral GLP-1R agonist for obesity) announced in September 2024. Planning to initiate Phase 2 trial for TERN-601 in 2025. Early clinical trial data on TERN-701 for CML expected in December 2024.
- Therapeutic areas
- OncologyEndocrinologyGastroenterology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
Beyond the preview
Go deeper on Terns Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Terns Pharmaceuticals.